Data on glycoprotein IIb/IIIa inhibitor( GPI) use in real-world acute coronary syndrome( ACS) patients following the introduction of potent P2 Y12 inhibitors and newer-generation stents are scant. In this paper, the authors aimed to assess the utilization, effectiveness, and safety of GPI in a large prospective multicentre cohort of contemporary ACS patients.

Read full article (European Heart Journal - Cardiovascular Pharmacotherapy (2024) 0 , 1–12)